MEDCL — Medincell SA Income Statement
0.000.00%
Last trade - 00:00
- €363.60m
- €400.03m
- €9.89m
2019 March 31st | 2020 March 31st | R2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1.44 | 2.85 | 8.19 | 4.09 | 9.89 |
Cost of Revenue | |||||
Gross Profit | 0.433 | 1.88 | 6.74 | 2.59 | 6.46 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 17 | 22.2 | 23.8 | 27.9 | 33.9 |
Operating Profit | -15.5 | -19.3 | -15.6 | -23.8 | -24 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -19.7 | -21.4 | -19 | -24.8 | -32 |
Provision for Income Taxes | |||||
Net Income After Taxes | -19.7 | -23.9 | -19 | -24.8 | -32 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -19.7 | -23.9 | -19 | -24.8 | -32 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -19.7 | -23.9 | -19 | -24.8 | -32 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.14 | -1.19 | -0.861 | -0.998 | -1.27 |
Dividends per Share |